Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer

被引：0
|
作者：
Cheryl S. W. Li
Kevin Sweeney
Carol Cronenberger
机构：
[1] Pfizer Global Product Development,Clinical Pharmacology/Pharmacometrics
[2] Pfizer Inc.,Clinical Pharmacology/Pharmacometrics
[3] Pfizer Global Product Development,Clinical Pharmacology/Pharmacometrics
[4] Pfizer Inc.,undefined
[5] Pfizer Global Product Development,undefined
[6] Pfizer Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 85卷
关键词：
Bevacizumab; Biosimilar; Non-small cell lung cancer; PF-06439535; Population pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：487 / 499
页数：12
相关论文
共 50 条
  • [31] Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer
    Hirai, Fumihiko
    Seto, Takashi
    Inamasu, Eiko
    Shimokawa, Mototsugu
    Toyokawa, Gouji
    Yoshida, Tsukihisa
    Nosaki, Kaname
    Takenaka, Tomoyoshi
    Yamaguchi, Masafumi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    ONCOLOGY LETTERS, 2015, 9 (06) : 2577 - 2582
  • [32] Eligibility for Bevacizumab as an Independent Prognostic Factor for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study
    Takagi, Yusuke
    Toriihara, Akira
    Nakahara, Yoshiro
    Yomota, Makiko
    Okuma, Yusuke
    Hosomi, Yukio
    Shibuya, Masahiko
    Okamura, Tatsuru
    PLOS ONE, 2013, 8 (03):
  • [33] First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naive patients
    Leon, Luis
    Vazquez, Sergio
    Manuel Gracia, Jose
    Casal, Joaquin
    Lazaro, Martin
    Luis Firvida, Jose
    Amenedo, Margarita
    Santome, Lucia
    Macia, Sonia
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (10) : 1389 - 1396
  • [34] Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial
    Mok, Tony S. K.
    Hsia, Te-Chun
    Tsai, Chun-Ming
    Tsang, Kenneth
    Chang, Gee-Chen
    Chang, John Wen-Cheng
    Thitiya, Sirisinha
    Sriuranpong, Virote
    Thongprasert, Sumitra
    Chua, Daniel T. T.
    Moore, Nicola
    Manegold, Christian
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 : 4 - 12
  • [35] Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: A retrospective study
    Habib, Stefanie
    Delourme, Julie
    Dhalluin, Xavier
    Petyt, Gregory
    Tacelli, Nunzia
    Scherpereel, Arnaud
    Lafitte, Jean-Jacques
    Cortot, Alexis B.
    LUNG CANCER, 2013, 80 (02) : 197 - 202
  • [36] Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)
    Patel, J. D.
    Hensing, T. A.
    Rademaker, F.
    Hart, E.
    Obasaju, C. K.
    Treat, J.
    Milton, D.
    Bonomi, P. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV non-squamous non-small cell lung cancer (STELLA): Design of a confirmatory, double-blind, randomized, controlled study.
    Shparyk, Yaroslav V.
    Bondarenko, Igor
    Paravisini, Alexandra
    Florez, Amalia
    Huerga, Camino
    Abad, Marta
    Bullo, Felicitas
    Millan, Susana
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naive patients with advanced non-squamous non-small cell lung cancer
    Takiguchi, Yuichi
    Iwasawa, Shunichiro
    Minato, Koichi
    Miura, Yosuke
    Gemma, Akihiko
    Noro, Rintaro
    Yoshimori, Kozo
    Shingyoji, Masato
    Hino, Mitsunori
    Ando, Masahiro
    Okamoto, Hiroaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 659 - 667
  • [39] Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
    Ko, Ryo
    Shukuya, Takehito
    Imamura, Chiyo K.
    Tokito, Takaaki
    Shimada, Naoko
    Koyama, Ryo
    Yamada, Kazuhiko
    Ishii, Hidenobu
    Azuma, Koichi
    Takahashi, Kazuhisa
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 183 - +
  • [40] EFFICIENCY OF CISPLATIN, PEMETREXED, AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR JAPANESE ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
    Shiraishi, Yoshimasa
    Hirai, Humihiko
    Yamaguchi, Masafumi
    Morodomi, Yosuke
    Toyozawa, Ryo
    Inamasu, Eiko
    Kojo, Miyako
    Toyokawa, Gouji
    Takenaka, Tomoyoshi
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S488 - S488
12345